Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) FCF Margin (2016 - 2025)

Historic FCF Margin for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to 24.12%.

  • Aytu Biopharma's FCF Margin rose 62500.0% to 24.12% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.11%, marking a year-over-year decrease of 14400.0%. This contributed to the annual value of 3.26% for FY2025, which is 6300.0% down from last year.
  • Per Aytu Biopharma's latest filing, its FCF Margin stood at 24.12% for Q4 2025, which was up 62500.0% from 4.45% recorded in Q3 2025.
  • Aytu Biopharma's FCF Margin's 5-year high stood at 146.11% during Q1 2021, with a 5-year trough of 38.11% in Q4 2021.
  • Its 5-year average for FCF Margin is 1.62%, with a median of 6.05% in 2024.
  • In the last 5 years, Aytu Biopharma's FCF Margin plummeted by -1837800bps in 2022 and then soared by 563400bps in 2023.
  • Quarter analysis of 5 years shows Aytu Biopharma's FCF Margin stood at 38.11% in 2021, then soared by 76bps to 9.33% in 2022, then soared by 92bps to 0.72% in 2023, then skyrocketed by 2582bps to 17.87% in 2024, then soared by 35bps to 24.12% in 2025.
  • Its FCF Margin stands at 24.12% for Q4 2025, versus 4.45% for Q3 2025 and 18.41% for Q2 2025.